Skip to main content
OMDA logo

OMDA · Omada Health, Inc.

Track OMDA — free
$11.87 -0.63 (-5.04%) At close · Nov 20
Market Cap
$736.39M
Shares
62.04M
Volume · Nov 20 1.71M Avg daily vol (3M) 1.32M

Price & Indicators

 

Key stats

Close
$11.87
Fri 20 Nov
Open
$12.29
Fri 20 Nov
Average volume, 30 days
1.3M
shares a session
Short interest
9.2M
14.8% of shares · 11.4 days to cover
Day range
$11.76$12.64
Open $12.29 Close $11.87
52-week closing range
$10.94$24.99
Close $11.87 52.5% under the high
Short volume, last session
39%
Last earnings
Nov 5, 2026
Latest filing
10-Q · Nov 6
Price history
Jun 2025 to Nov 2026

Up next

Mar 4, 2027 Est · unconfirmed · in 15 wks

Latest documents

2026
Nov 6
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 34% to $91,306 thousand as company turns profitable

Omada Health reported third-quarter 2026 total revenue of $91,306 thousand, up 34% from $68,030 thousand a year earlier. Operating income was $4,820 thousand, compared with a loss of $(2,513) thousand, and net income was $6,551 thousand versus a net loss of $(3,178) thousand. Total members reached 1,134,000 as of September 30, 2026.

Revenue $91.31M ▲ 34.2% Net income $6.55M Diluted EPS $0.10
Read from the MD&A section
4 source passages
| Total revenue | 91,306 | 68,030 | 23,276 | 34% | 257,189 | 184,364 | 72,825 | 40% | | Operating income (loss) | 4,820 | (2,513) | 3,588 | (15,253) | | Net income (loss) and comprehensive income (loss) | 6,551 | (3,178) | 8,875 | (17,937) | As of September 30, 2026, we had approximately 1,134,000 total members enrolled in one or more programs. Open the document at this passage
Nov 5
Earnings call
Raises 2026 outlook after record profitable quarter

Omada Health raised its full-year 2026 revenue outlook to $344 million to $346 million and adjusted EBITDA guidance to $32 million to $34 million, after Q3 revenue rose 34% to $91 million and net income reached nearly $7 million.

6 source passages
Welcome to Omada Health's third quarter 2026 earnings conference call. Our Q3 performance and our visibility into the fourth quarter give us the confidence to raise our full-year 2026 revenue and adjusted EBITDA outlook. We expect full-year revenue to range from $344 million to $346 million, up from our prior guidance of $334 million to $340 million. We are also raising full-year adjusted EBITDA guidance to $32 million to $34 million, up from prior guidance of $21 million to $27 million. Q3 revenue reached $91 million, up 34% year-over-year and approximately 4% sequentially from $88 million in Q2. Gap net income for Q3 was nearly $7 million, compared with a gap net loss of approximately $3 million in Q3 of last year, an improvement of approximately $10 million. Open the document at this passage
Nov 5
Current report 8-K
Revenue grows 34%, members reach 1.1 million, outlook raised

Omada Health reported third-quarter revenue of $91 million, up 34%, and 1.1 million Total Members, up 36%. It raised 2026 revenue guidance to $344 million to $346 million and Adjusted EBITDA guidance to $32 million to $34 million.

Financial results
6 source passages
Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the third quarter ended September 30, 2026. Revenue Grew 34% and Total Members Increased 36% Year over Year •Revenue of $91 million, compared with total revenue of $68 million in Q3 2025 •Total Members reached 1.1 million, increasing 36% year over year, reflecting continued demand across Omada Health's integrated cardiometabolic care platform and strong enrollment momentum across diabetes and hypertension programs. •Revenue in the range of $344 million to $346 million, up from prior guidance of $334 million to $340 million, with the midpoint representing approximately 33% growth compared with 2025. •Adjusted EBITDA in the range of $32 million to $34 million, up from prior guidance of $21 million to $27 million, with the midpoint representing an improvement of approximately $27 million, or roughly five and a half times, compared with 2025. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$333.04M
Trailing 12 months
Net income (TTM)
$14.03M
Trailing 12 months
Revenue growth YoY
+34.2%
Year over year
Operating margin
2.1%
Trailing 12 months
P / E (TTM)
9.7
Trailing earnings · reciprocal yield 10.4%
FCF yield
3.8%
TTM · current market cap
Return on invested capital
22.9%
Trailing 12 months
Net cash
$243.15M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+16.4%
Year over year · more shares
Price change (1Y)
-34.7%
Trailing year
Short interest
14.8%
Latest settlement · 11.4 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 5, 2026
Q3 FY26

TL;DR. Omada raised full-year revenue and adjusted EBITDA guidance after Q3 delivered 34% revenue growth, 36% member growth, record profitability, higher margins, and approximately $243 million of cash with no debt. The outlook includes lower Q4 revenue, a slight Q4 membership step-down, and moderating adjusted EBITDA, while GLP-1 coverage uncertainty, rising healthcare costs, and customer concentration remain risks.

Bullish
  • + Reduced non-GAAP cost of revenue per total member to an all-time low of $81, down from $85 in Q2 and $94 in Q3 2025.
Bearish
  • − Expects Q4 revenue to be below Q3 because of lower new enrollment and engagement activity during the holidays.
  • − Expects Q4 adjusted EBITDA to moderate from Q3 as R&D and care-team staffing increase for the 2027 benefit launch.
  • − GAAP operating expenses increased to 71% of revenue from 70% a year earlier.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −33%
below
Price vs 50-day avg −36%
below
RSI (14) 23
oversold
MACD trend Negative
52-week position 7%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −37%
trailing
6-month return −33%
trailing
YTD return −25%
this year
Relative strength −24%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $18 › 200d $18 — 50d above 200d
Institutional flow Accumulating
+26% holders QoQ · +58 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
14.77% of shares out · ▲ +9.8% MoM · 11.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
193 holders — near 1-yr high, broad support
Squeeze score 74
high risk · 0–100
Fundamentals
Excellent
Revenue growth +53%
Y/Y
Gross margin 66%
expanding
EPS growth +94%
Y/Y
Free cash flow $16.9M
Balance sheet $222.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 65%
annualized · 1-yr
Max drawdown −53%
past year
ATR 9.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Nov 5, 2026
full-year 2026
Full-year revenue Raised $344M – $346M
Aug 6, 2026 $334M – $340M changed to Nov 5, 2026 $344M – $346M
prior FY $260.21M midpoint +32.6% Y/Y
Adjusted EBITDA Non-GAAP Raised $32M – $34M
Aug 6, 2026 $21M – $27M changed to Nov 5, 2026 $32M – $34M
longer-term
Gross margin target 80%
Prior guidance period ended · from the 8-K filed Jan 12, 2026
Preliminary, unaudited revenue · fourth quarter of 2025 $72M – $74M
Preliminary revenue · full year 2025 $256M – $258M
Guided vs delivered · last 1 settled
Revenue year ending December 31, 2025
guided $251.5M – $254.5M
$260.21M Beat +2.8%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−33% Bearish
Price vs 50-day avg
−36% Bearish
RSI (14)
23 Neutral
MACD trend
Negative Bearish
52-week position
7% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $18 › 200d $18 — 50d above 200d
Institutional flow Accumulating
+26% holders QoQ · +58 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
14.77% of shares out · ▲ +9.8% MoM · 11.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
193 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $11 Now $12 · 7% Range high $25
vs 200-day avg -33% vs 50-day avg -36%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Free Cash Flow non-GAAP 2.46M nine months ended September 30, 2026 —
Non-GAAP gross margin (as a percentage of revenue) non-GAAP 73% nine months ended September 30, 2026 —
Total Members 1.1M third quarter 2026 —
Trailing 12-month revenue per Total Member $294 trailing 12-month period ended September 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Health Information Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
OMDA
Omada Health, Inc.
this stock
$736.39M -24.8% +53.2% — 14.8%
VEEV
Veeva Systems Inc
$43.10B +19.3% +28.1% 43.6 2.4%
PMDIY
Pro Medicus Ltd.
$14.81B -14.6% — — 0.0%
BTSG
BrightSpring Health Services, Inc.
$12.50B +67.8% +28.2% 34.2 5.8%
TEM
Tempus AI, Inc.
$9.86B -8.5% +83.4% — 13.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
193
% held
93.4%
Net QoQ
+5.3M sh
Top holder
Divisadero Street Capital…
Held Float
View
Held by Funds
Fund positions
135
View
Short & Settlement
Short Interest Rising
Shares short
9.2M
Days to cover
11.4d
Change
+817.6K sh
View
Short Volume
Short vol %
39%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
106
Value
$2.1K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
39.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$260.2M
Net income (FY)
$-12.8M
EPS diluted
$-0.35
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 6, 2026
This year
16

Omada Health reported third-quarter 2026 total revenue of $91,306 thousand, up 34% from $68,030 thousand a year earlier. Operating income was $4,820 thousand, compared with a loss of $(2,513) thousand, and net income was $6,551 thousand versus a net loss of $(3,178) thousand. Total members reached 1,134,000 as of September 30, 2026.

View
Proposed Sales
Value
$240.5K
Shares
12.9K
Filed
Nov 4, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Omada Health Presents AI-Powered…
Published
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
OMDA -17.2% -37.4% -33.3% -36.6% -24.8%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -8.6% -28.1% -24.1% -27.9% -25.9%
Key facts CIK 1611115 CUSIP 68170A108 13F (30d) 173 filings 171 filers Visit website Investor relations